Patients with primary Sjogren's syndrome more likely to develop subclinical atherosclerosis
Patients with primary Sjogren's syndrome more likely to develop subclinical atherosclerosis than control group suggests a new study published in the European Journal of Internal Medicine.
Currently, the guidelines for prevention and management of atherosclerosis in patients with Sjogren's syndrome (SS) do not differentiate from those concerning the general population.
The present systematic review aimed to summarize evidence from primary studies assessing the risk of subclinical atherosclerosis in patients with primary SS (pSS).
Literature was searched until June 2023. Eligible records were randomized controlled trials and observational studies comparing subclinical atherosclerosis markers between pSS patients and healthy controls. DerSimonian-Laird random effects models were used to calculate overall effect estimates. Totally, 19 observational studies comprising 1625 participants were included. Compared to healthy controls, pSS patients had significantly higher values of carotid-femoral intima-media thickness (cfIMT) (MD= 0.07 mm; 95 % CI= [0.04, 0.11]; p <0.001) and were more frequently diagnosed with atherosclerotic plaques (OR= 1.9; 95 % CI= [1.32, 2.74]; p <0.001). Moreover, pSS patients showed a decreased flow and nitrate-mediated dilation (MD = -2.48 %; 95 % CI= [-4.57, -0.39]; p = 0.02, MD= -2.11 %; 95 % CI= [-3.22, -1.01]; p <0.001, respectively). Similar results were observed for the pulse-wave velocity (MD= 0.7 m/s; 95 % CI= [0.36, 1.05]; p <0.001) and the ankle-brachial index (OR= 5.78; 95 % CI= [2.23, 14.99]; p = 0.003). Based on meta-regression analyses, only the disease duration and erythrocyte sedimentation rate were positively and significantly associated with higher cfIMT values.
Conclusion
Patients with pSS have an increased risk of subclinical atherosclerosis compared to healthy population and thus possibly require early and disease-specific intervention. Further research is warranted for more accurate cardiovascular risk management in SS.
Reference:
Risk of subclinical atherosclerosis in primary Sjogren's syndrome: A systematic review and meta-analysis. Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Konstantinos I. Bougioukas, Theodoros Dimitroulas, Nikolaos Fragakis. Show all authors
Published:November 15, 2023DOI:https://doi.org/10.1016/j.ejim.2023.11.007
Keywords:
Patients, primary Sjogren's syndrome more likely to develop subclinical atherosclerosis than control group, European Journal of Internal Medicine, Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Konstantinos I. Bougioukas, Theodoros Dimitroulas, Nikolaos Fragakis, Sjogren's syndrome, Autoimmune diseases, Atherosclerosis, Intima-media thickness, Atherosclerotic plaque
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.